Prima BioMed (NASDAQ:IMMP) Shares Cross Below 50-Day Moving Average – Here’s Why

Prima BioMed Ltd (NASDAQ:IMMP)’s share price crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $0.45 and traded as low as $0.3550. Prima BioMed shares last traded at $0.3703, with a volume of 225,835 shares changing hands.

Analyst Ratings Changes

A number of brokerages have recently issued reports on IMMP. Citizens Jmp cut shares of Prima BioMed from an “outperform” rating to a “market perform” rating in a research note on Friday, March 13th. Wall Street Zen raised shares of Prima BioMed to a “hold” rating in a research note on Saturday, April 18th. Maxim Group cut shares of Prima BioMed from a “buy” rating to a “hold” rating in a research note on Friday, March 13th. Finally, Robert W. Baird cut shares of Prima BioMed from an “outperform” rating to a “neutral” rating and cut their price objective for the company from $7.00 to $1.00 in a research note on Friday, March 13th. Three research analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Prima BioMed currently has an average rating of “Reduce” and an average target price of $5.50.

Prima BioMed Trading Up 1.8%

The company’s 50-day simple moving average is $0.45 and its two-hundred day simple moving average is $1.67.

Institutional Investors Weigh In On Prima BioMed

A hedge fund recently raised its stake in Prima BioMed stock. Jane Street Group LLC raised its position in shares of Prima BioMed Ltd (NASDAQ:IMMP) by 14.7% in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 51,574 shares of the biotechnology company’s stock after buying an additional 6,617 shares during the period. Jane Street Group LLC’s holdings in Prima BioMed were worth $91,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 2.32% of the company’s stock.

About Prima BioMed

Prima BioMed, trading as IMMP on NASDAQ, is a clinical-stage biotechnology company specializing in the development of immunotherapy products for cancer treatment. The company’s core technology platform centers on targeting the lymphocyte activation gene-3 (LAG-3), a checkpoint receptor that modulates T-cell activity. Prima BioMed’s lead candidate, eftilagimod alpha (IMP321), is a soluble LAG-3 protein designed to enhance antigen-presenting cell function and stimulate a tumor-specific immune response.